The University of Birmingham and Acticor Biotech announced the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction. In 2022, the University of Birmingham and Actic or Biotech signed a partnership agreement to evaluate glenzocim AB efficacy in myocardial infARction in a new clinical trial called LIBERATE. Having obtained full regulatory approval in August 2023, two cutting-edge clinical research sites, namely the Queen Elizabeth Hospital in Birmingham and the Northern General Hospital in Sheffield, are involved in the study.

The primary objective of the study is to evaluate both the safety and efficacy of glenzocimab at a dosage of 1000 mg compared to a placebo, specifically focusing on the reduction of myocardial infarct size at Day 90 post-treatment. Dr. Mark Thomas, Associate Professor of Cardiology at the University of Birmingham and Honorary Consultant Cardiologist and Director of the Cardiovascular Research Unit at Northern General Hospital, said: "We are very happy to have started recruit into the LIBERATE clinical trial. This is the first time worldwide that this class of medication has been investigated in patients with heart attacks, after showing great promise in patients with stroke.

The company are very pleased to now recruit patients in the LIBERATE clinical trial".